We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Corcept Therapeutics to Report Q1 Earnings: What's in the Cards?
Read MoreHide Full Article
We expect investors to focus on the sales performance of Corcept Therapeutics’ (CORT - Free Report) sole-marketed drug, Korlym (mifepristone), which is approved for treating Cushing's syndrome or endogenous hypercortisolism, when the company reports first-quarter 2025 results on May 5, after market close.
The Zacks Consensus Estimate for the to-be-reported quarter’s revenues is pegged at $177.97 million, while the same for earnings is pegged at 17 cents per share. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar).
Year to date, shares of Corcept have risen 40.8% against the industry’s decline of 4%.
Image Source: Zacks Investment Research
Factors to Note Ahead of CORT's Q1 Results
Corcept’s top line solely comprises product sales from Korlym.
Korlym sales increased year over year in the last reported quarter, driven by continued strong demand, a trend most likely to have continued in the first quarter.
Corcept has been making good progress with its lead pipeline candidate, relacorilant.
The company has been developing relacorilant for treating patients with Cushing’s syndrome. In December 2024, CORT submitted a new drug application (NDA) for relacorilant to the FDA for the same.
In March 2025, the FDA accepted the NDA and assigned a Prescription Drug User Fee Act target action date of Dec. 30, 2025.
Corcept is also evaluating relacorilant in combination studies for treating different types of cancer indications.
Corcept plans to submit a new drug application in the United States in the third quarter of 2025, while a marketing authorization application in Europe is likely to be filed shortly thereafter. Investors will be keen to get more updates on the same during the upcoming earnings call.
Activities related to label expansion studies and other development activities might have escalated operating expenses in the to-be-reported quarter.
Earnings Surprise History
Corcept has a mixed history of earnings surprises. The company beat on earnings in three of the trailing four quarters while missing the same on the remaining occasion, delivering an average surprise of 20.08%. In the last reported quarter, CORT delivered a negative earnings surprise of 29.73%.
Corcept Therapeutics Incorporated Price and EPS Surprise
Our proven model does not conclusively predict an earnings beat for Corcept this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold) increases the odds of an earnings beat. That is not the case here, as you will see below. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Earnings ESP: Corcept has an Earnings ESP of -9.09% as the Most Accurate Estimate currently stands at 15 cents per share and the Zacks Consensus Estimate is pegged at 17 cents per share.
Zacks Rank: CORT currently carries a Zacks Rank #3.
Stocks to Consider
Here are some biotech stocks that have the right combination of elements to beat on earnings this time around:
CytomX Therapeutics (CTMX - Free Report) has an Earnings ESP of +38.89% and a Zacks Rank #2 at present.
CytomX Therapeutics’ shares have plunged 31.3% year to date. CTMX beat on earnings in three of the trailing four quarters and missed in the other one, delivering an average surprise of 180.70%.
argenx (ARGX - Free Report) has an Earnings ESP of +10.92% and a Zacks Rank #3 at present.
argenx stock has increased 1% in the year-to-date period. ARGX beat on earnings in two of the last four quarters and missed in the other two, delivering an average surprise of 345.11%. ARGX is scheduled to report first-quarter results on May 8.
Blueprint Medicines (BPMC - Free Report) has an Earnings ESP of +84.44% and a Zacks Rank #3 at present.
Blueprint Medicines stock has risen 1.5% year to date. BPMC beat on earnings in three of the trailing four quarters and missed in the other one, delivering an average surprise of 13.10%. BPMC is scheduled to report first-quarter results on May 1.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Corcept Therapeutics to Report Q1 Earnings: What's in the Cards?
We expect investors to focus on the sales performance of Corcept Therapeutics’ (CORT - Free Report) sole-marketed drug, Korlym (mifepristone), which is approved for treating Cushing's syndrome or endogenous hypercortisolism, when the company reports first-quarter 2025 results on May 5, after market close.
The Zacks Consensus Estimate for the to-be-reported quarter’s revenues is pegged at $177.97 million, while the same for earnings is pegged at 17 cents per share. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar).
Year to date, shares of Corcept have risen 40.8% against the industry’s decline of 4%.
Image Source: Zacks Investment Research
Factors to Note Ahead of CORT's Q1 Results
Corcept’s top line solely comprises product sales from Korlym.
Korlym sales increased year over year in the last reported quarter, driven by continued strong demand, a trend most likely to have continued in the first quarter.
Corcept has been making good progress with its lead pipeline candidate, relacorilant.
The company has been developing relacorilant for treating patients with Cushing’s syndrome. In December 2024, CORT submitted a new drug application (NDA) for relacorilant to the FDA for the same.
In March 2025, the FDA accepted the NDA and assigned a Prescription Drug User Fee Act target action date of Dec. 30, 2025.
Corcept is also evaluating relacorilant in combination studies for treating different types of cancer indications.
The phase III ROSELLA study, which evaluated relacorilant, in combination with nab-paclitaxel for treating patients with platinum-resistant ovarian cancer, met its primary endpoint of improved progression-free survival (PFS).
Corcept plans to submit a new drug application in the United States in the third quarter of 2025, while a marketing authorization application in Europe is likely to be filed shortly thereafter. Investors will be keen to get more updates on the same during the upcoming earnings call.
Activities related to label expansion studies and other development activities might have escalated operating expenses in the to-be-reported quarter.
Earnings Surprise History
Corcept has a mixed history of earnings surprises. The company beat on earnings in three of the trailing four quarters while missing the same on the remaining occasion, delivering an average surprise of 20.08%. In the last reported quarter, CORT delivered a negative earnings surprise of 29.73%.
Corcept Therapeutics Incorporated Price and EPS Surprise
Corcept Therapeutics Incorporated price-eps-surprise | Corcept Therapeutics Incorporated Quote
Earnings Whispers
Our proven model does not conclusively predict an earnings beat for Corcept this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold) increases the odds of an earnings beat. That is not the case here, as you will see below. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Earnings ESP: Corcept has an Earnings ESP of -9.09% as the Most Accurate Estimate currently stands at 15 cents per share and the Zacks Consensus Estimate is pegged at 17 cents per share.
Zacks Rank: CORT currently carries a Zacks Rank #3.
Stocks to Consider
Here are some biotech stocks that have the right combination of elements to beat on earnings this time around:
CytomX Therapeutics (CTMX - Free Report) has an Earnings ESP of +38.89% and a Zacks Rank #2 at present.
CytomX Therapeutics’ shares have plunged 31.3% year to date. CTMX beat on earnings in three of the trailing four quarters and missed in the other one, delivering an average surprise of 180.70%.
argenx (ARGX - Free Report) has an Earnings ESP of +10.92% and a Zacks Rank #3 at present.
argenx stock has increased 1% in the year-to-date period. ARGX beat on earnings in two of the last four quarters and missed in the other two, delivering an average surprise of 345.11%. ARGX is scheduled to report first-quarter results on May 8.
Blueprint Medicines (BPMC - Free Report) has an Earnings ESP of +84.44% and a Zacks Rank #3 at present.
Blueprint Medicines stock has risen 1.5% year to date. BPMC beat on earnings in three of the trailing four quarters and missed in the other one, delivering an average surprise of 13.10%. BPMC is scheduled to report first-quarter results on May 1.